As the availability and utilization of ultra-high-cost, long-term specialty products such as GLP-1s and cell and gene therapies grows, HR decision-makers and pharmacy consultants must embrace a more ...
Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...
Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...
A SPAC deal with RA Capital–sponsored RACC is expected to yield ~$175 million gross, including a fully backstopped trust and PIPE/SAFE financing, with closing targeted by end of 2026. Rugonersen, an ...
Since then, that mindset has continued to grow at AbbVie.
This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...
Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...
FDA authorization covers adults and children ≥6 years (≥20 kg) for once-daily centanafadine ER, positioned as a CNS stimulant with a first-in-class NDSRI mechanism. Evidence derived from four pivotal ...
Narrow votes supported compounding of BPC-157, KPV, and TB-500 (8-6; one abstention) and MOTS-c (7-5; two abstentions), without constituting FDA approval or demonstrated clinical benefit. Regulatory ...
Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or ...
In today's Pharmaceutical Executive Daily, an FDA advisory panel narrowly votes to recommend easing restrictions on four unapproved peptides, a supply chain expert discusses how China's export ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results